a PR in January 2013 about Moffitt's Phase 1 feasibility study to elucidate PV-10's bystander effect, Moffitt's Dr. Amod Sarnaik, MD was quoted as "We look forward to verifying the promising pre-clinical data from our ongoing work in this translational study. These results should help elucidate the immunologic basis of the 'bystander effect' noted in previous clinical studies of PV-10 and help optimize PV-10 treatment, particularly in combination with other therapies. As Moffitt pursues its mission of contributing to the prevention and cure of cancer, we are pleased to spearhead this important clinical work."
It appears this work has been completed, preliminary results or interim analysis are available, the bystander effect has been elucidated, and Moffitt already has moved on to combining PV-10 with other notable categories of treatments, such as immunotherapies (i.e., anti-CTLA-4, anti-PD-1 and anti-PDL-1 agents).
Moffitt and, more specifically, Dr. Weber, are critical and key to PV-10 and Provectus, having been notably involved in translational studies and other work contributing greatly to the approvals of, among other treatments and therapies, ipilimumab (Yervoy) and vemurafenib (Zelboraf).